Commonwealth Equity Services
TRVI icon

Commonwealth Equity Services’s Trevi Therapeutics TRVI Stock Holding History

Commonwealth Equity Services’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$33K – 3801
2022
Q1 		$33K Buy
+15,000
New +$15.5K ﹤0.01% 3621

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Commonwealth Equity Services's TRVI Position: Q2 2022 in Review

Commonwealth Equity Services sold out of Trevi Therapeutics (TRVI) in Q2 2022, closing a stake of 15,000 shares — an estimated $33K sold.

Commonwealth Equity Services first reported a position in TRVI in Q1 2022 and held it in 1 quarter. The position peaked at $33K in Q1 2022. 32 funds tracked by Wall St. Rank hold TRVI as of Q2 2022.

  • Commonwealth Equity Services reported no remaining Trevi Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 15,000 Trevi Therapeutics shares in Q2 2022, an estimated $33K.
  • Commonwealth Equity Services first reported a position in Trevi Therapeutics in Q1 2022 and held it in 1 quarter.
  • Commonwealth Equity Services's Trevi Therapeutics position peaked at $33K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2022.

Based on Commonwealth Equity Services's 13F filing for Q2 2022, filed 19 Jul 2022.